Jaguar Health, Inc.: Jaguar Health to Present at the H.C. Wainwright BIOCONNECT 2021 Virtual Conference the Week of January 11th and at 4:30 pm Eastern on Tuesday, January 19th at the NobleCon17 Virtual Conference
Jaguar CEO Lisa Conte interviewed on Innovators with Jane King
SAN FRANCISCO, CA / ACCESSWIRE / January 12, 2021 / Jaguar Health, Inc. (NASDAQ:JAGX) announced today announced that Lisa Conte, Jaguar s founder, president and CEO, will present at the H.C. Wainwright BIOCONNECT 2021 virtual conference the week of January 11, 2021 and at 4:30 pm Eastern on Tuesday, January 19, 2021 at the NobleCon17 conference.
Event Details:
Conference Dates: January 11-14, 2021
Jaguar Presentation: Presentation available on-demand during the week of January 11-14, 2021
Jaguar Health to Present at the H C Wainwright BIOCONNECT 2021 Virtual Conference the Week of January 11th and at 4:30 pm Eastern on Tuesday, January 19th at the NobleCon17 Virtual Conference
newjerseytelegraph.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from newjerseytelegraph.com Daily Mail and Mail on Sunday newspapers.
Jaguar Health Exploring Possibility of Conditional Marketing Authorization for Proposed Inflammatory Diarrhea Indication for Crofelemer, Initially in Long-Hauler COVID-19 Recovery Patients in Europe
phoenixherald.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from phoenixherald.com Daily Mail and Mail on Sunday newspapers.
Why Jaguar Health Stock Skyrocketed 49% Today Joe Tenebruso
What happened
Shares of
Jaguar Health (NASDAQ: JAGX) soared 49.3% on Friday, extending the pharmaceutical company s staggering gains since mid-November.
So what
Jaguar Health s stock price is up a stunning 2,062% since its lows on Nov. 16. Investors have bid up the healthcare stock after management announced its plan to develop and commercialize crofelemer, a new drug aimed at helping people with inflammatory diarrhea, including those who have recovered from COVID-19 but are still experiencing symptoms.
Jaguar Health said the plan could involve a potential merger of its operating subsidiary with Swiss Growth Forum, a sponsor of a special purpose acquisition company (SPAC). Preliminary terms of the deal include Jaguar Health receiving upfront cash payments of as much as $10 million and at least $20 million in clinical development funding, as well as an equity stake in the new company of 30% to 4